Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 4

Conditions

Asthma

Treatments

Drug: Fluticasone/Salmeterol HFA

Study type

Interventional

Funder types

Industry

Identifiers

NCT00404261

108835

Details and patient eligibility

About

The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter, as compared to using Fluticasone/Salmeterol HFA MDI without counter.

Enrollment

132 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Outpatient
Documented physician diagnosis of asthma or COPD
Requires use of a controller and long acting beta 2 agonist
Ability to provided written informed consent

Exclusion criteria

Patients with life threatening asthma or COPD
Historical or current evidence of significant diseases
Immediate or delayed hypersensitivity to inhaled short acting beta2agonist or sympathomimetic drug or any component of the MDI formulation
History of drug or alcohol abuse Abnormal chest x ray not consistent with asthma or COPD
Use of supplemental oxygen; systemic corticosteroids; short acting beta2agonists other than VENTOLIN HFA; antibiotics for respiratory infections; anti-arrhythmics; anticonvulsants; central nervous system stimulants; tricyclic antidepressants and monoamine oxidase inhibitors.